公开(公告)号：US12116602B2

公开(公告)日：2024-10-15

申请号：US17930943

申请日：2022-09-09

申请人： Mayo Foundation for Medical Education and Research

发明人： Liyi Geng ,  Ping Chen ,  William S. Brimijoin ,  Yang Gao

IPC分类号： C12N9/18 ,  C07K14/00 ,  C07K14/575 ,  C12N7/00 ,  C12N15/86 ,  A61K35/76 ,  A61K35/761 ,  A61K38/00 ,  A61K38/22 ,  A61K48/00 ,  C07H21/04 ,  C12N15/861 ,  C12N15/864

CPC分类号： C12N9/18 ,  C07K14/00 ,  C07K14/5759 ,  C12N7/00 ,  C12N15/86 ,  C12Y301/01008 ,  A61K35/76 ,  A61K35/761 ,  A61K38/00 ,  A61K38/2264 ,  A61K48/00 ,  C07H21/04 ,  C12N15/861 ,  C12N15/8645 ,  C12N2750/14141 ,  C12N2750/14143

摘要： This document provides butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin as well as nucleic acids encoding such butyrylcholinesterases. This document also provides methods and materials for treating obesity and/or aggression. For example, methods for administering a nucleic acid encoding a wild-type or mutant butyrylcholinesterase having the ability to hydrolyze acyl ghrelin to a mammal under conditions wherein the level of acyl ghrelin within the mammal is reduced, under conditions wherein the rate of body weight gain of the mammal is reduced, under conditions wherein the mammal's level of aggression is reduced, and/or under conditions wherein the mammal's rate of developing stress-induced tissue damage are provided.

公开(公告)号：US20240335489A1

公开(公告)日：2024-10-10

申请号：US18751599

申请日：2024-06-24

申请人： Baylor College of Medicine ,  United States Government as Represented by the Department of Veterans Affairs

发明人： Anthony Maresso ,  Robert Ramig ,  Sabrina Green ,  Austen Terwilliger ,  Keiko Salazar ,  Justin R. Clark ,  Barbara Trautner

IPC分类号： A61K35/76 ,  A61P31/04 ,  C12N7/00

CPC分类号： A61K35/76 ,  A61P31/04 ,  C12N7/00 ,  C12N2795/10132 ,  C12N2795/10171 ,  C12N2795/10232 ,  C12N2795/10271

摘要： Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

公开(公告)号：US20240307511A1

公开(公告)日：2024-09-19

申请号：US18538866

申请日：2023-12-13

申请人： The Trustees of the University of Pennsylvania

发明人： Christian Hinderer ,  James M. Wilson

IPC分类号： A61K38/47 ,  A61K9/00 ,  A61K31/343 ,  A61K31/439 ,  A61K35/76 ,  A61K45/06 ,  A61K48/00 ,  A61P3/00 ,  C12N7/00 ,  C12N9/24 ,  C12N15/86

CPC分类号： A61K38/47 ,  A61K9/0019 ,  A61K31/343 ,  A61K31/439 ,  A61K35/76 ,  A61K45/06 ,  A61P3/00 ,  C12N7/00 ,  C12N9/2402 ,  C12N15/86 ,  C12Y302/01076 ,  A61K48/00 ,  A61K48/0083 ,  C12N2750/14121 ,  C12N2750/14132 ,  C12N2750/14143

摘要： A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene and two or more immunosuppressants is provided herein. Also provided are methods useful for treating hIDUA deficiency (MPSI) and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.

公开(公告)号：US12084698B2

公开(公告)日：2024-09-10

申请号：US17258288

申请日：2019-07-12

申请人： KYOTO UNIVERSITY

发明人： Akitsu Hotta ,  Peter David Gee

IPC分类号： C12N9/90 ,  A61K31/436 ,  A61K35/76 ,  C07K14/16 ,  C12N7/00 ,  C12N9/22 ,  C12N15/113 ,  C12N15/62 ,  C12N15/87

CPC分类号： C12N9/90 ,  A61K31/436 ,  A61K35/76 ,  C07K14/161 ,  C12N7/00 ,  C12N9/22 ,  C12N15/113 ,  C12N15/625 ,  C12N15/87 ,  C12Y502/00

摘要： A virus-like particle encapsulating a target protein is provided. The virus-like particle contain a Gag protein, and the Gag protein forms a dimer with the target protein.

公开(公告)号：US12084687B2

公开(公告)日：2024-09-10

申请号：US16324541

申请日：2017-08-09

申请人： CITY OF HOPE

发明人： Yuman Fong ,  Nanhai Chen

IPC分类号： C12N7/00 ,  A61K35/76 ,  A61K39/275 ,  A61P35/00 ,  C07K14/47 ,  C07K16/28 ,  C12N15/86

CPC分类号： C12N7/00 ,  A61K35/76 ,  A61K39/275 ,  A61P35/00 ,  C07K14/47 ,  C07K16/2827 ,  C12N15/86 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/76 ,  C12N2710/24121 ,  C12N2710/24132 ,  C12N2710/24143 ,  C12N2710/24151

摘要： Provided herein are, inter alia, viral compositions and methods of using the same. The viral compositions provided include, inter alia, therapeutically effective amounts of a chimeric poxvirus and are particularly useful for methods of treating cancer. The chimeric poxviruses provided herein may further include transgenes.

公开(公告)号：US12070478B2

公开(公告)日：2024-08-27

申请号：US18115066

申请日：2023-02-28

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Nicole F. Steinmetz ,  Karin L. Lee

IPC分类号： A61K35/76 ,  A61K31/704 ,  A61K39/12 ,  A61K39/39 ,  A61P35/00 ,  C12N7/00 ,  A61K45/06

CPC分类号： A61K35/76 ,  A61K31/704 ,  A61K39/12 ,  A61K39/39 ,  A61P35/00 ,  A61K45/06 ,  C12N2770/26011 ,  C12N2770/26023 ,  C12N2770/26033 ,  C12N2770/26042 ,  C12N2770/40023

摘要： A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

公开(公告)号：US20240277791A1

公开(公告)日：2024-08-22

申请号：US18568574

申请日：2022-06-10

申请人： Integrated Pharma Services, LLC

发明人： Mina Izadjoo ,  Hosan Kim ,  Salman Izadjoo

IPC分类号： A61K35/76 ,  A61K9/00 ,  A61K9/06 ,  A61K38/16 ,  A61K38/47 ,  A61K47/34 ,  A61K47/38 ,  A61P17/10 ,  A61P31/04 ,  C07K14/005 ,  C12N7/00 ,  C12N9/36

CPC分类号： A61K35/76 ,  A61K9/0014 ,  A61K9/06 ,  A61K38/162 ,  A61K38/47 ,  A61K47/34 ,  A61K47/38 ,  A61P17/10 ,  A61P31/04 ,  C07K14/005 ,  C12N7/00 ,  C12N9/2462 ,  C12Y302/01017 ,  C12N2795/00021 ,  C12N2795/00022 ,  C12N2795/00032

摘要： Recombinantly-modified Cutibacterium acnes-specific bacteriophage, and recombinantly modified bacteriophage-derived endolysin enzyme are provided. Such compositions, alone or in combination with other antimicrobial agents or immunomodulators, may be used in pharmaceutical compositions, particularly pharmaceutical compositions to treat acne, promote wound healing, inhibit the growth of biofilms and to decrease the likelihood of, prevent or treat surgical related infections. The present invention is particularly directed to such formulations that are compounded for topical administration to a subject or used for application to medical devices. In particular, such pharmaceutical compositions may be compounded for topical administration to a subject, or compounded for application to a medical device.

公开(公告)号：US12064460B2

公开(公告)日：2024-08-20

申请号：US16964142

申请日：2019-01-25

申请人： TOKUSHIMA UNIVERSITY ,  JICHI MEDICAL UNIVERSITY ,  GENE THERAPY RESEARCH INSTITUTION CO., LTD.

发明人： Kohji Itoh ,  Daisuke Tsuji ,  Shinichi Muramatsu ,  Katsuhito Asai

IPC分类号： A61K35/76 ,  A61P25/28 ,  C12N7/00

CPC分类号： A61K35/76 ,  A61P25/28 ,  C12N7/00 ,  C12N2750/14121 ,  C12N2750/14143 ,  C12N2750/14171

摘要： According to a conventional method for treatment of Sandhoff disease and Tay-Sachs disease comprising administering a modified β-subunit to a patient in the form of a protein, it is necessary that administration be performed frequently. This invention relates to a recombinant adeno-associated virus virion comprising: capsomere comprising a protein capable of forming a virus virion; and a polynucleotide packaged in the capsomere comprising a promoter sequence and nucleotide sequences operably linked to the promoter sequence encoding a first amino acid sequence derived from the amino acid sequence of the β-subunit of wild-type human β-hexosaminidase composed of amino acids 55 to 556 in the sequence as shown in SEQ ID NO: 28 by substitution of amino acids 312 to 318 with glycine, serine, glutamic acid, proline, serine, glycine, and threonine in that order and a second amino acid sequence, which is an amino acid sequence of a signal peptide linked to the N terminus of the first amino acid.

公开(公告)号：US12059443B2

公开(公告)日：2024-08-13

申请号：US17130349

申请日：2020-12-22

申请人： PrimeVax Immuno-Oncology, Inc.

发明人： Bruce W. Lyday

IPC分类号： A61K35/76 ,  A61K9/00 ,  A61K9/19 ,  A61P35/00 ,  C12N7/00

CPC分类号： A61K35/76 ,  A61K9/0019 ,  A61K9/19 ,  A61P35/00 ,  C12N7/00 ,  C12N2770/24121 ,  C12N2770/24132

摘要： Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.

公开(公告)号：US12037608B2

公开(公告)日：2024-07-16

申请号：US16606685

申请日：2018-04-18

申请人： THE UNIVERSITY OF TOKYO ,  NPT CO., LTD.

发明人： Yang Jia ,  Shohei Miyamoto ,  Kenichiro Hara ,  Atsuhumi Iwanaga ,  Kenzaburo Tani

IPC分类号： C12N7/00 ,  A61K9/00 ,  A61K35/76 ,  A61P35/00 ,  C12N15/11 ,  C12N15/113

CPC分类号： C12N7/00 ,  A61K9/0014 ,  A61K35/76 ,  A61P35/00 ,  C12N15/11 ,  C12N15/1131 ,  C12N15/1135 ,  C12N2310/141 ,  C12N2770/32321 ,  C12N2770/32333

摘要： A gene-modified coxsackievirus that is to be used in oncolytic virotherapy and is improved in safety and/or aggressiveness is provided. A gene-modified coxsackievirus that contains a mutated genome with a coxsackievirus B3 wild-type (CVB3-WT) genome inserted with at least one polynucleotide constituted of a target sequence for at least one of either of miR-34a and miR-34c and is suppressed in proliferation in normal cells is provided.